Preserve the tumor microenvironment
CybridScope assesses the live biopsy's viability, tumor content, and response to immunotherapy over time ex vivo using a set of assays and instruments. Our advanced imaging technology has the capability to unlock novel insights into the tumor microenvironment.
Preserve the tumor microenvironment
Tumor assessment and response to therapy
Cloud data aggregation and analysis
Our technology and world-class team put Elephas at the frontier of preserving the live, native tumor microenvironment from tumor tissues. Limited amounts of tumor tissue available from clinically relevant core needle biopsies present a challenge for ex vivo profiling that requires a unique solution. The amount of tissue from a biopsy is small and heterogeneous in content and cellularity. Our solution allows for assessment of immunotherapy response from the complete specimen to overcome challenges with heterogeneity.
Our technology nondestructively measures data capture at multiple time points (i.e. over 48-72 hours) while maintaining the tumor microenvironment. Cytokine profiles and tumor content analysis informs the assessment of tumor response to immunotherapy.
Multiphoton microscopy (MPM) enables deep tissue penetration with minimal disruption to live cells. This proprietary technology is crucial for observing intricate biological processes and evaluating drug efficacy within live tissue structures.
Multiphoton fluorescence lifetime imaging microscopy (MP-FLIM) enables non-destructive longitudinal assessment of drug agents in intact tumor tissue without the use of disruptive probes, the Elephas approach is a label-free method to quantify the health of individual cells in biopsied tumor tissue.
MPM: Two fields of view from the same tumor, demonstrating the heterogeneity inherent in tumors.
Cas-Green (detects apoptosis); CD8 (T cell); NAD(P)H (metabolism); SHG (extracellular matrix/collagen)
Read the latest data behind our platform.
Stay up to date on our platform.